Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NOX4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length Lentivirus) | NOX4 Full-Length Lentivirus; HEK293 expressed, preserves 6-TM conformation for ROS generation assays. Sequence Verified. | View NOX4 Products |
| Antigen (Recombinant Protein) | NOX4 Recombinant Protein (Selected Domains / Custom Full-Length); Multi-pass membrane target. HEK293 Expressed. Endotoxin <1EU/µg. Sequence Verified. | View NOX4 Products |
| Gene Delivery | NOX4 Promise-ORF / Lentivirus; Full-length ORF for stable cell lines. Optional bicistronic p22phox co-expression vector for native oxidase activity. | View NOX4 Products |
| Benchmark Ab | Anti-NOX4 Recombinant Antibody; Rabbit mAb sequence; High purity (>95%); for Western, Flow, IHC assay development. | View NOX4 Products |
| Isoform Panel | NOX1, NOX2 (gp91phox) Proteins; For selectivity screening against NADPH oxidase family. High Purity (>95%). | View NOX1 Products |
| Validator | NOX4 siRNA Set; For knockdown verification in ROS inhibition studies; Endotoxin Controlled. | View NOX4 Products |
| Related Target: NOX1 | Vascular and hepatic isoform; key for selectivity profiling and compensation studies. | View NOX1 Products |
| Related Target: CYBA (p22phox) | Essential NOX4 stabilizing partner; co-expression required for native oxidase activity; PPI assays. | View CYBA Products |
| Related Target: RAC1 | Cytosolic regulator required for NOX complex assembly; critical for PPI assays. | View RAC1 Products |
| Related Target: TGFB1 | Upstream cytokine driving NOX4 expression in fibrosis; combination therapy partner. | View TGFB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native membrane conformation & oxidase activity (NOX4 requires p22phox for stability) | NOX4 Lentivirus with full-length ORF; Optional bicistronic p22phox; HEK293 background for native glycosylation and membrane insertion; compatible with downstream ROS detection assays. |
| Isoform selectivity (NOX1 vs NOX4 vs NOX2) | Human NOX1, NOX2, NOX4 recombinant domain proteins and cell lines available; Sequence verified by mass spec for strict homolog panel screening. |
| Cross-species activity evaluation | Human / Mouse / Cyno ortholog proteins and lentiviral ORFs for translational pharmacology. |
| Functional ROS Readout | Full-length NOX4 stable cell lines compatible with Amplex Red/NBT assays; Endotoxin <1EU/ug. |
| Target engagement & knockdown verification | Sequence-verified siRNA and recombinant anti-NOX4 antibody as detection control; Validated siRNA included for on-target confirmation. |
Live NOX4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NOX4 therapeutics is intensifying, with major players shifting focus from non-specific antioxidants to isoform-selective NADPH oxidase inhibitors. As first-generation small molecules (Setanaxib/GKT831/Calliditas) reach Phase 3 for primary biliary cholangitis and Phase 2 for idiopathic pulmonary fibrosis and diabetic nephropathy, the next wave of R&D is targeting highly selective NOX4 inhibitors to avoid the immunosuppressive side effects of NOX2 inhibition. Combination therapies with TGF-beta inhibitors, FXR agonists, and immune checkpoint blockers represent the frontier, particularly in fibrosis (NASH, SSc) and solid tumor oncology. Antisense oligonucleotides (IONIS) and emerging biologics are also in preclinical stages, aiming for precise tissue delivery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Genkyotex (Sobi, Calliditas), AstraZeneca, Healios | IPF, PBC, CKD, NASH | Isoform Selectivity Assay (Need NOX1/NOX2/NOX4 panel & cell lines) |
| Antisense Oligonucleotide | IONIS Pharmaceuticals | Cardiovascular, Diabetic Nephropathy | Knockdown Efficiency Assay (Need siRNA controls & cell lines) |
| Biologic (mAb / Nanobody) | Emerging preclinical | Cancer (TME modulation), Fibrosis | Cell-based ROS Assay (Need stable NOX4/p22phox line & antibody controls) |
| Combination Therapy | Novartis, Boehringer Ingelheim | Fibrosis + Inflammation | Pathway crosstalk assays (Need RAC1/TGFB1 co-reagents) |
Key Differentiation Strategies for NOX4 Drug Discovery
Selectivity (NOX4 vs NOX1 vs NOX2): Best-in-class drugs require >50-fold selectivity over NOX1 and >100-fold over NOX2 to avoid infections. Use TarMart’s isoform panels with mass-spec verified recombinant domains.
Mechanism of Inhibition: NOX4 generates H2O2 constitutively; long-dwell-time inhibitors needed. Use stable cell lines with 24-48h ROS kinetic assays (Amplex Red).
Allosteric Sites: Targeting the NOX4-p22phox interface disrupts complex assembly. Use PPI assays (AlphaLISA/TR-FRET) with full-length NOX4/p22phox complex.
Tissue Penetration: Fibrotic liver/kidney require drug access to hepatic stellate cells/podocytes. Use primary cell assays (e.g., HSC) rather than HEK293-only models.
TarMart provides the essential reagents: lentiviral particles for cell line construction, recombinant proteins for selectivity panels, siRNAs for target engagement, and antibodies for detection.